Efficacy and safety of HarQ on menopausal symptoms; A 12week, Randomized, Doubleblind, Placebo-Controlled Clinical Trial

Konkuk University Medical Center0 个研究点目标入组 120 人开始时间: 待定最近更新: 2019年5月20日

试验速览

暂无简介。

•1) Women 40 to 65 years of age who are in the menopause (12 months or more)
•2) Women with a KMI (kupperman index) score of 20 or higher
•3) Women who have agreed to participate in this trial before the start of the clinical trial and who have written an informed consent form

•1) Women who have surgical or chemotherapy induced menopause
•2) Women who have undergone hysterectomy
•3) Women with a history of endometrial hyperplasia, endometrial cancer, breast disease, sex hormone related cancer
•4) Patients with uncontrolled hypertension(160/100mmHg or higher, after 10 minutes of clinical test subjects)
•5) A woman with a history of severe migraine within the past 1 year, diagnosed with thromboembolism, cerebrovascular disease, myocardial infarction, unstable angina, or coronary angioplasty
•6) A person whose ALT and AST exceed 3 times the normal upper limit
•7) A person whose Creatinine exceed 2 times the normal upper limit
•8) who are not considrered to be appropriate to particiapt on this study

发起方